According to FDA, the new drug can be used by postmenopausal patients who are not using any other cancer drugs. The new FDA approved drug is developed by the pharmaceutical company Pfizer Inc.
The new cancer drug is called Ibrance and can be used to help treat the tumors that don’t contain a certain protein called HER-2 and have been known to be receptive to the hormone estrogen.
The new cancer drug approved by FDA called Ibrance is also known under the name of palbociclib.
According to medical experts, Ibrance will prove to be a success in cancer treatment and could sell up to $4 billion by the year 2020.
Ibrance must be used with another medication for cancer known as letrozole.
An FDA representative, Dr. Richard Pazdur, said that the new cancer drug Ibrance in combination with letrozole can provide a new treatment for women who have been diagnosed with metastatic breast cancer.
Pfizer Inc. released a statement in which it specifies the price of their new drug Ibrance. According to the press release, the drug is either $9,85 a month or $118,2 for a yearly price.
The manufacturing company also announced that its new drug will be made available through various health plans, which can negotiate the price of the drugs. Also, the patients can benefit from discounts mandated by the government.
According to FDA, the new Ibrance cancer drug was initially up for approval in April, but because of the positive results following the clinical tests, the drug was approved earlier.
The scientists tested the new Ibrance drug on 165 patients. The results showed that the drug helped slow down the progression of the breast cancer.
According to the study, the patients who took Ibrance in combination with letrozole lived an average of 20 months before the tumors got worse. The researchers said that the study is still continuing.
Breast cancer is one of the most common forms of cancer among women in the United States. According to the National Cancer Institute, approximately 232,600 women are diagnosed with breast cancer in the US annually.
Image Source: yahoo